Viewing Study NCT06794957


Ignite Creation Date: 2025-12-24 @ 6:32 PM
Ignite Modification Date: 2025-12-24 @ 6:32 PM
Study NCT ID: NCT06794957
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-01-27
First Post: 2024-01-30
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of AL8326 in Non-Small Cell Lung Cancer
Sponsor: Advenchen Laboratories, LLC
Organization:

Study Overview

Official Title: A Single-Arm, Open, Phase Ib Study Evaluating the Safety, Preliminary Efficacy of AL8326 in the Treatment of Non-Small Cell Lung Cancer
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.
Detailed Description: The subjects received the test drug al8326 tablets in the order of enrollment (oral administration, once a day, one cycle every 28 days) until intolerable toxicity or disease progression or death or voluntary withdrawal or the end of this study. The subjects will conduct anti-tumor efficacy evaluation and corresponding safety inspection every 2 cycles, and determine the tumor disease status according to the solid tumor efficacy evaluation criteria (RECIST 1.1).

Subjects requiring pharmacokinetic analysis will be randomly treated with trial drug AL8326 tablets 60mg QD or 40mg QD (oral administration, once a day, one cycle every 28 days) in a 1:1 ratio.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: